- Home
- CRGX vs ESQ Comparison
CRGX vs ESQ Comparison
Compare CRGX & ESQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- ESQ
- Stock Information
- Founded
- CRGX 2021
- ESQ 2006
- Country
- CRGX United States
- ESQ United States
- Employees
- CRGX N/A
- ESQ N/A
- Industry
- CRGX
- ESQ Commercial Banks
- Sector
- CRGX
- ESQ Finance
- Exchange
- CRGX Nasdaq
- ESQ Nasdaq
- Market Cap
- CRGX 190.0M
- ESQ 756.3M
- IPO Year
- CRGX 2023
- ESQ 2017
- Fundamental
- Price
- CRGX $4.46
- ESQ $99.25
- Analyst Decision
- CRGX Hold
- ESQ Hold
- Analyst Count
- CRGX 7
- ESQ 3
- Target Price
- CRGX $4.67
- ESQ $95.00
- AVG Volume (30 Days)
- CRGX 502.9K
- ESQ 124.2K
- Earning Date
- CRGX 08-11-2025
- ESQ 07-24-2025
- Dividend Yield
- CRGX N/A
- ESQ 0.71%
- EPS Growth
- CRGX N/A
- ESQ 13.51
- EPS
- CRGX N/A
- ESQ 5.27
- Revenue
- CRGX N/A
- ESQ $124,132,000.00
- Revenue This Year
- CRGX $57.81
- ESQ N/A
- Revenue Next Year
- CRGX N/A
- ESQ $10.72
- P/E Ratio
- CRGX N/A
- ESQ $18.84
- Revenue Growth
- CRGX N/A
- ESQ 14.72
- 52 Week Low
- CRGX $3.00
- ESQ $46.10
- 52 Week High
- CRGX $25.45
- ESQ $99.75
- Technical
- Relative Strength Index (RSI)
- CRGX 57.89
- ESQ 70.61
- Support Level
- CRGX $4.09
- ESQ $93.57
- Resistance Level
- CRGX $4.51
- ESQ $99.75
- Average True Range (ATR)
- CRGX 0.18
- ESQ 3.03
- MACD
- CRGX 0.00
- ESQ 0.65
- Stochastic Oscillator
- CRGX 77.18
- ESQ 94.55
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About ESQ Esquire Financial Holdings Inc.
Esquire Financial Holdings Inc is a financial holding company. Through its subsidiary, the company operates as a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. In addition, it operates a payment processing platform through third-party independent sales organizations.